Novartis, Cephalon Disease-Modifying Parkinson’s Drugs Near Late Stages
Executive Summary
Novartis' and Cephalon's disease-modifying Parkinson's disease agents are approaching the final stages of development, with at least one pivotal trial slated to begin in 2004
You may also be interested in...
Pharmos’ dexanabinol (correction)
Pharmos' Phase III trial for its cannabinoid dexanabinal in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end. FDA placed the NMDA antagonist on fast track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease as suggested in the 1March 22 issue of "The Pink Sheet" (p. 38)...
Pharmos’ dexanabinol (correction)
Pharmos' Phase III trial for its cannabinoid dexanabinal in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end. FDA placed the NMDA antagonist on fast track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease as suggested in the 1March 22 issue of "The Pink Sheet" (p. 38)...
Axonyx Phenserine May Be First Alzheimer's Drug Targeting Beta-Amyloid
Axonyx' phenserine could be the first Alzheimer's disease agent targeting beta-amyloid plaques filed at FDA as companies look to move beyond the symptom relief offered by current therapies